Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Market Manipulation Continues

<< Previous

Bullboard Posts

Next >>

Comment by stocksarefunon Dec 07, 2021 9:24am

93 Views

Post# 34205636

RE:Market Manipulation Continues

Couldn't have said it any better.

this market is ripe with manipulation, no way around that. Bigger exchanges will bring smarter manipulators. The real problem we have here is a lack of bids, and a lack of demand. Hoping that the third party review is a US Entity that will provide US exposure, because that's where the money and biotech demand is from institutions.

The Press release, while it exceeded my expectations, failed to disclose anything about US participation, funding, investment, or acknowledgement. That, in my opinion, is the ticket to liftoff.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market